Recombinant MDV1 Vaccine Vector for Interference-Free Poultry Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing recombinant HVT-based vaccines face interference issues when used in combination to confer immunogenicity against multiple pathogens, leading to reduced protection against certain diseases.
Innovation Solution
Development of recombinant Marek's Disease Virus of serotype 1 (rMDV1) with a recombinant nucleic acid located in the MDV086.6 locus, allowing stable expression of foreign genes and compatible use with other viral vaccines for extended immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If recombinant HVT-based vaccines are used in combination to confer immunogenicity against multiple pathogens, then the duration of immunity is extended, but the protection level against certain diseases is reduced due to interference
Solution Approach 1:
The patent divides the vaccination strategy by using different viral vectors for different antigen expressions. Instead of using HVT for multiple antigens (which causes interference), the invention segments the approach by using MDV1 for one antigen and HVT for another, allowing each vector to optimize its performance for specific pathogens without mutual interference.
Solution Approach 2:
The patent introduces MDV1 as an intermediary viral vector to replace HVT in specific vaccination combinations. This intermediary vector (MDV1) performs the function of carrying and expressing antigens without causing the interference problems that HVT exhibits when used in combination vaccines, thus mediating between the need for extended immunity and the need for reliable protection.
2Adaptability or versatility
If recombinant viruses express multiple foreign genes for multivalent vaccination, then the versatility of the vaccine is improved, but the stability of virus replication and immunogenicity is reduced
Solution Approach 1:
The patent segments the multivalent vaccination function across different viral vectors rather than consolidating multiple antigens in a single HVT vector. Each vector (MDV1 or HVT) carries a limited number of antigens, maintaining viral stability and replication efficiency while achieving multivalent protection through the coordinated use of multiple vectors.
Solution Approach 2:
The patent employs multiple viral vectors (both MDV1 and HVT) that each possess universal capabilities to express foreign genes and elicit immune responses. By utilizing the multi-functionality of different vector systems, the invention achieves multivalent vaccination without overloading a single vector system, thereby maintaining the stability of each individual virus.
3Duration of action of stationary object
If foreign genes are integrated into HVT genome for viral-vectored vaccination, then the duration of immunity is extended, but the complexity of vaccine formulation increases
Solution Approach 1:
The patent segments the vaccine formulation complexity by using standardized, well-characterized viral vectors (MDV1 and HVT) with known integration behaviors. Each vector follows established protocols for foreign gene integration, simplifying the overall formulation process compared to developing novel integration systems, while still achieving extended immunity through persistent viral expression.
Data Source
AI summary
The present invention relates recombinant viruses and the uses thereof. More particularly, the invention relates to novel recombinant Marek's disease viruses encoding polypeptide(s) of interest, and their use to express or deliver such polypeptides to animals, particularly poultry. The invention is particularly suited to vaccinate poultry against avian pathogens.